Decoding drug resistant mechanism of V32I, I50V and I84V mutations of HIV-1 protease on amprenavir binding by using molecular dynamics simulations and MM-GBSA calculations

References

• B. Poon, K. Grovit-Ferbas, S.A. Stewart, and I.S.Y. Chen, Cell cycle arrest by vpr in HIV-1 virions and insensitivity to antiretroviral agents, Science 281 (1998), pp. 266–269. doi:10.1126/science.281.5374.266.
   PubMed Web of Science ®Google Scholar
• M.A. Navia, P.M.D. Fitzgerald, B.M. McKeever, C.-T. Leu, J.C. Heimbach, W.K. Herber, I.S. Sigal, P.L. Darke, and J.P. Springer, Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1, Nature 337 (1989), pp. 615–620. doi:10.1038/337615a0.
   PubMed Web of Science ®Google Scholar
• A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard, and D.D. Ho, HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time, Science 271 (1996), pp. 1582–1586. doi:10.1126/science.271.5255.1582.
   PubMed Web of Science ®Google Scholar
• E.O. Freed, HIV-1 gag proteins: Diverse functions in the virus life cycle, Virology 251 (1998), pp. 1–15. doi:10.1006/viro.1998.9398.
   PubMed Web of Science ®Google Scholar
• A. Wlodawer and J. Vondrasek, Inhibitors of HIV-1 PROTEASE: A major success of structure-assisted drug design, Annu. Rev. Bioph. Biom. 27 (1998), pp. 249–284. doi:10.1146/annurev.biophys.27.1.249.
   PubMedGoogle Scholar
• R. Lapatto, T. Blundell, A. Hemmings, J. Overington, A. Wilderspin, S. Wood, J.R. Merson, P.J. Whittle, D.E. Danley, K.F. Geoghegan, S.J. Hawrylik, S.E. Lee, K.G. Scheld, and P.M. Hobart, X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes, Nature 342 (1989), pp. 299–302. doi:10.1038/342299a0.
   PubMed Web of Science ®Google Scholar
• R. Ishima, D.I. Freedberg, Y.-X. Wang, J.M. Louis, and D.A. Torchia, Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function, Structure 7 (1999), pp. S1–S12. doi:10.1016/S0969-2126(99)80172-5.
   PubMed Web of Science ®Google Scholar
• W.R.P. Scott and C.A. Schiffer, Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance, Structure 8 (2000), pp. 1259–1265. doi:10.1016/S0969-2126(00)00537-2.
   PubMed Web of Science ®Google Scholar
• A. Carr, K. Samaras, D.J. Chisholm, and D.A. Cooper, Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance, Lancet 351 (1998), pp. 1881–1883. doi:10.1016/S0140-6736(98)03391-1.
   PubMed Web of Science ®Google Scholar
• D.A. Judd, J.H. Nettles, N. Nevins, J.P. Snyder, D.C. Liotta, J. Tang, J. Ermolieff, R.F. Schinazi, and C.L. Hill, Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition, J. Am. Chem. Soc. 123 (2001), pp. 886–897. doi:10.1021/ja001809e.
   PubMed Web of Science ®Google Scholar
• A.Y. Kovalevsky, F. Liu, S. Leshchenko, A.K. Ghosh, J.M. Louis, R.W. Harrison, and I.T. Weber, Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114, J. Mol. Biol. 363 (2006), pp. 161–173. doi:10.1016/j.jmb.2006.08.007.
   PubMed Web of Science ®Google Scholar
• A.K. Ghosh, Z.L. Dawson, and H. Mitsuya, Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV, Bioorg. Med. Chem. 15 (2007), pp. 7576–7580. doi:10.1016/j.bmc.2007.09.010.
   PubMed Web of Science ®Google Scholar
• A.Y. Kovalevsky, J.M. Louis, A. Aniana, A.K. Ghosh, and I.T. Weber, Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease, J. Mol. Biol. 384 (2008), pp. 178–192. doi:10.1016/j.jmb.2008.09.031.
   PubMed Web of Science ®Google Scholar
• G.M. Lee and C.S. Craik, Trapping moving targets with small molecules, Science 324 (2009), pp. 213–215. doi:10.1126/science.1169378.
   PubMed Web of Science ®Google Scholar
• G.C. Williams and P.J. Sinko, Oral absorption of the HIV protease inhibitors: A current update, Adv. Drug Deliver. Rev. 39 (1999), pp. 211–238. doi:10.1016/S0169-409X(99)00027-7.
   PubMed Web of Science ®Google Scholar
• C.-H. Shen, Y.-F. Wang, A.Y. Kovalevsky, R.W. Harrison, and I.T. Weber, Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters, FEBS J. 277 (2010), pp. 3699–3714. doi:10.1111/j.1742-4658.2010.07771.x.
   PubMed Web of Science ®Google Scholar
• D.L.N.G. Surleraux, A. Tahri, W.G. Verschueren, G.M.E. Pille, H.A. De Kock, T.H.M. Jonckers, A. Peeters, S. De Meyer, H. Azijn, R. Pauwels, M.-P. de Bethune, N.M. King, M. Prabu-Jeyabalan, C.A. Schiffer, and P.B.T.P. Wigerinck, Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor, J. Med. Chem. 48 (2005), pp. 1813–1822. doi:10.1021/jm049560p.
   PubMed Web of Science ®Google Scholar
• H. Heaslet, V. Kutilek, G.M. Morris, Y.-C. Lin, J.H. Elder, B.E. Torbett, and C.D. Stout, Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3, J. Mol. Biol. 356 (2006), pp. 967–981. doi:10.1016/j.jmb.2005.11.094.
   PubMed Web of Science ®Google Scholar
• M. Kožíšek, J. Bray, P. Řezáčová, K. Šašková, J. Brynda, J. Pokorná, F. Mammano, L. Rulíšek, and J. Konvalinka, Molecular analysis of the HIV-1 resistance development: Enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants, J. Mol. Biol. 374 (2007), pp. 1005–1016. doi:10.1016/j.jmb.2007.09.083.
   PubMed Web of Science ®Google Scholar
• S. Muzammil, A.A. Armstrong, L.W. Kang, A. Jakalian, P.R. Bonneau, V. Schmelmer, L.M. Amzel, and E. Freire, Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations, J. Virol. 81 (2007), pp. 5144–5154. doi:10.1128/JVI.02706-06.
   PubMed Web of Science ®Google Scholar
• D.A. Ragland, E.A. Nalivaika, M.N.L. Nalam, K.L. Prachanronarong, H. Cao, R.M. Bandaranayake, Y. Cai, N. Kurt-Yilmaz, and C.A. Schiffer, Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease, J. Am. Chem. Soc. 136 (2014), pp. 11956–11963. doi:10.1021/ja504096m.
   PubMed Web of Science ®Google Scholar
• J. Agniswamy, C.-H. Shen, Y.-F. Wang, A.K. Ghosh, K.V. Rao, C.-X. Xu, J.M. Sayer, J.M. Louis, and I.T. Weber, Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with p1′-pyrrolidinone or p2-tris-tetrahydrofuran, J. Med. Chem. 56 (2013), pp. 4017–4027. doi:10.1021/jm400231v.
   PubMed Web of Science ®Google Scholar
• G. Leonis, T. Steinbrecher, and M.G. Papadopoulos, A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation i50v: A systematic mm–pbsa and thermodynamic integration study, J. Chem. Inf. Model. 53 (2013), pp. 2141–2153. doi:10.1021/ci4002102.
   PubMed Web of Science ®Google Scholar
• J. Chen, S. Zhang, X. Liu, and Q. Zhang, Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: Free energy calculation and molecular dynamic simulation, J. Mol. Model. 16 (2010), pp. 459–468. doi:10.1007/s00894-009-0553-7.
   PubMed Web of Science ®Google Scholar
• A.Y. Kovalevsky, A.A. Chumanevich, F. Liu, J.M. Louis, and I.T. Weber, Caught in the act:  The 1.5 Å resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate, Biochemistry-US 46 (2007), pp. 14854–14864. doi:10.1021/bi700822g.
   PubMed Web of Science ®Google Scholar
• A.M. Borman, S. Paulous, and F. Clavel, Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug, J. Gen. Virol. 77 (1996), pp. 419–426. doi:10.1099/0022-1317-77-3-419.
   PubMed Web of Science ®Google Scholar
• R. Duan, R. Lazim, and D. Zhang, Understanding the basis of I50V-induced affinity decrease in HIV-1 protease via molecular dynamics simulations using polarized force field, J. Comput. Chem. 36 (2015), pp. 1885–1892. doi:10.1002/jcc.24020.
   PubMed Web of Science ®Google Scholar
• D.S. Clutter, P.R. Sánchez, S.-Y. Rhee, and R.W. Shafer, Genetic variability of HIV-1 for drug resistance assay development, Viruses 8 (2016), pp. 48. doi:10.3390/v8020048.
   Web of Science ®Google Scholar
• Y. Tie, Y.-F. Wang, P.I. Boross, T.-Y. Chiu, A.K. Ghosh, J. Tozser, J.M. Louis, R.W. Harrison, and I.T. Weber, Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors, Protein Sci. 21 (2012), pp. 339–350. doi:10.1002/pro.2019.
   PubMed Web of Science ®Google Scholar
• S. Pazhanisamy, C.M. Stuver, A.B. Cullinan, N. Margolin, B.G. Rao, and D.J. Livingston, Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants, J. Biol. Chem. 271 (1996), pp. 17979–17985. doi:10.1074/jbc.271.30.17979.
   PubMed Web of Science ®Google Scholar
• F. Liu, A.Y. Kovalevsky, Y. Tie, A.K. Ghosh, R.W. Harrison, and I.T. Weber, Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir, J. Mol. Biol. 381 (2008), pp. 102–115. doi:10.1016/j.jmb.2008.05.062.
   PubMed Web of Science ®Google Scholar
• G.-D. Hu, T. Zhu, S.-L. Zhang, D. Wang, and Q.-G. Zhang, Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations, Eur. J. Med. Chem. 45 (2010), pp. 227–235. doi:10.1016/j.ejmech.2009.09.048.
   PubMed Web of Science ®Google Scholar
• P. Kar and V. Knecht, Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir, J. Comput. Aid. Mol. Des. 26 (2012), pp. 215–232. doi:10.1007/s10822-012-9550-5.
   PubMed Web of Science ®Google Scholar
• K. Wittayanarakul, O. Aruksakunwong, S. Saen-oon, W. Chantratita, V. Parasuk, P. Sompornpisut, and S. Hannongbua, Insights into saquinavir resistance in the G48V HIV-1 protease: Quantum calculations and molecular dynamic simulations, Biophys. J. 88 (2005), pp. 867–879. doi:10.1529/biophysj.104.046110.
   PubMed Web of Science ®Google Scholar
• N.M. King, M. Prabu-Jeyabalan, R.M. Bandaranayake, M.N.L. Nalam, E.A. Nalivaika, A. Özen, T. Haliloǧlu, N.K. Yılmaz, and C.A. Schiffer, Extreme entropy–enthalpy compensation in a drug-resistant variant of HIV-1 protease, ACS Chem. Biol. 7 (2012), pp. 1536–1546. doi:10.1021/cb300191k.
   PubMed Web of Science ®Google Scholar
• M. Kolli, A. Özen, N. Kurt-Yilmaz, C.A. Schiffer, and W.I. Sundquist, HIV-1 protease-substrate coevolution in nelfinavir resistance, J. Virol. 88 (2014), pp. 7145–7154. doi:10.1128/JVI.00266-14.
   PubMed Web of Science ®Google Scholar
• J.L. Paulsen, F. Leidner, D.A. Ragland, N. Kurt Yilmaz, and C.A. Schiffer, Interdependence of inhibitor recognition in HIV-1 protease, J. Chem. Theor. Comput. 13 (2017), pp. 2300–2309. doi:10.1021/acs.jctc.6b01262.
   PubMed Web of Science ®Google Scholar
• S.N. Khan, J.D. Persons, J.L. Paulsen, M. Guerrero, C.A. Schiffer, N. Kurt-Yilmaz, and R. Ishima, Probing structural changes among analogous inhibitor-bound forms of HIV-1 protease and a drug-resistant mutant in solution by nuclear magnetic resonance, Biochemistry-US 57 (2018), pp. 1652–1662. doi:10.1021/acs.biochem.7b01238.
   PubMed Web of Science ®Google Scholar
• W. Xue, F. Yang, P. Wang, G. Zheng, Y. Chen, X. Yao, and F. Zhu, What contributes to serotonin–norepinephrine reuptake inhibitors’ dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation, ACS Chem. Neurosci. 9 (2018), pp. 1128–1140. doi:10.1021/acschemneuro.7b00490.
   PubMed Web of Science ®Google Scholar
• J. Chen, S. Zhang, Q. Zeng, W. Wang, Q. Zhang, and X. Liu, Free energy profiles relating with conformational transition of the switch domains induced by G12 mutations in GTP-bound KRAS, Front. Mol. Biosci. 9 (2022), pp. 912518. doi:10.3389/fmolb.2022.912518.
   PubMed Web of Science ®Google Scholar
• J. Chen, S. Zhang, W. Wang, L. Pang, Q. Zhang, and X. Liu, Mutation-induced impacts on the switch transformations of the GDP- and GTP-bound K-ras: Insights from multiple replica Gaussian accelerated molecular dynamics and free energy analysis, J. Chem. Inf. Model. 61 (2021), pp. 1954–1969. doi:10.1021/acs.jcim.0c01470.
   PubMed Web of Science ®Google Scholar
• G. Hu, A. Ma, and J. Wang, Ligand selectivity mechanism and conformational changes in guanine riboswitch by molecular dynamics simulations and free energy calculations, J. Chem. Inf. Model. 57 (2017), pp. 918–928. doi:10.1021/acs.jcim.7b00139.
   PubMed Web of Science ®Google Scholar
• J. Wang and Y. Miao, Mechanistic insights into specific G protein interactions with adenosine receptors, J. Phys. Chem. B 123 (2019), pp. 6462–6473. doi:10.1021/acs.jpcb.9b04867.
   PubMed Web of Science ®Google Scholar
• S. Liang, X. Liu, S. Zhang, M. Li, Q. Zhang, and J. Chen, Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations, Phys. Chem. Chem. Phys. 24 (2022), pp. 1743–1759. doi:10.1039/D1CP04361G.
   PubMed Web of Science ®Google Scholar
• J. Devillers, C. Lagneau, A. Lattes, J.C. Garrigues, M.M. Clémenté, and A. Yébakima, In silico models for predicting vector control chemicals targeting Aedes aegypti, SAR QSAR Environ. Res. 25 (2014), pp. 805–835. doi:10.1080/1062936X.2014.958291.
   PubMed Web of Science ®Google Scholar
• J. Wang and Y. Miao, Peptide Gaussian accelerated molecular dynamics (Pep-GaMD): Enhanced sampling and free energy and kinetics calculations of peptide binding, J. Chem. Phys. 153 (2020), pp. 154109. doi:10.1063/5.0021399.
   PubMed Web of Science ®Google Scholar
• W. Xue, P. Wang, G. Tu, F. Yang, G. Zheng, X. Li, X. Li, Y. Chen, X. Yao, and F. Zhu, Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder, Phys. Chem. Chem. Phys. 20 (2018), pp. 6606–6616. doi:10.1039/C7CP07869B.
   PubMed Web of Science ®Google Scholar
• S.S. Liang, X.G. Liu, Y.X. Cui, S.L. Zhang, Q.G. Zhang, and J.Z. Chen, Molecular mechanism concerning conformational changes of CDK2 mediated by binding of inhibitors using molecular dynamics simulations and principal component analysis, SAR QSAR Environ. Res. 32 (2021), pp. 573–594. doi:10.1080/1062936X.2021.1934896.
   Web of Science ®Google Scholar
• J. Chen, B. Yin, W. Wang, and H. Sun, Effects of disulfide bonds on binding of inhibitors to β-amyloid cleaving enzyme 1 decoded by multiple replica accelerated molecular dynamics simulations, ACS Chem. Neurosci. 11 (2020), pp. 1811–1826. doi:10.1021/acschemneuro.0c00234.
   PubMed Web of Science ®Google Scholar
• C. Wang, D.A. Greene, L. Xiao, R. Qi, and R. Luo, Recent developments and applications of the MMPBSA method, Front. Mol. Biosci. 4 (2018), pp. 87. doi:10.3389/fmolb.2017.00087.
   PubMed Web of Science ®Google Scholar
• H. Tzoupis, G. Leonis, T. Mavromoustakos, and M.G. Papadopoulos, A comparative molecular dynamics, MM–PBSA and thermodynamic integration study of saquinavir complexes with wild-type HIV-1 PR and L10I, G48V, L63P, A71V, G73S, V82A and I84V single mutants, J. Chem. Theory Comput. 9 (2013), pp. 1754–1764. doi:10.1021/ct301063k.
   PubMed Web of Science ®Google Scholar
• J. Chen, X. Wang, L. Pang, J.Z.H. Zhang, and T. Zhu, Effect of mutations on binding of ligands to guanine riboswitch probed by free energy perturbation and molecular dynamics simulations, Nucleic Acids Res. 47 (2019), pp. 6618–6631. doi:10.1093/nar/gkz499.
   PubMed Web of Science ®Google Scholar
• J. Devillers, Computational Design of Chemicals for the Control of Mosquitoes and Their Diseases, CRC Press, Boca Raton, 2018.
   Google Scholar
• A. Badaya and Y.U. Sasidhar, Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations, Sci. Rep-UK 10 (2020), pp. 5501. doi:10.1038/s41598-020-62423-y.
   PubMed Web of Science ®Google Scholar
• F. Leidner, N. Kurt Yilmaz, J. Paulsen, Y.A. Muller, and C.A. Schiffer, Hydration structure and dynamics of inhibitor-bound HIV-1 protease, J. Chem. Theory Comput. 14 (2018), pp. 2784–2796. doi:10.1021/acs.jctc.8b00097.
   PubMed Web of Science ®Google Scholar
• I. Ancy, M. Sivanandam, and P. Kumaradhas, Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: A molecular docking, molecular dynamics and binding free energy simulation study, J. Biomol. Struct. Dyn. 39 (2021), pp. 5368–5375. doi:10.1080/07391102.2020.1786459.
   PubMed Web of Science ®Google Scholar
• S. Shi, S. Zhang, and Q. Zhang, Insight into binding mechanisms of inhibitors MKP56, MKP73, MKP86, and MKP97 to HIV-1 protease by using molecular dynamics simulation, J. Biomol. Struct. Dyn. 36 (2018), pp. 981–992. doi:10.1080/07391102.2017.1305296.
   PubMed Web of Science ®Google Scholar
• R.-G. Wang, H.-X. Zhang, and Q.-C. Zheng, Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses, Phys. Chem. Chem. Phys. 22 (2020), pp. 4464–4480. doi:10.1039/C9CP06657H.
   PubMed Web of Science ®Google Scholar
• R. Wang and Q. Zheng, Multiple molecular dynamics simulations and free-energy predictions uncover the susceptibility of variants of HIV-1 protease against inhibitors darunavir and KNI-1657, Langmuir 37 (2021), pp. 14407–14418. doi:10.1021/acs.langmuir.1c02348.
   PubMed Web of Science ®Google Scholar
• Y.X. Yu, W.T. Liu, H.Y. Li, W. Wang, H.B. Sun, L.L. Zhang, and S.L. Wu, Decoding molecular mechanism underlying binding of drugs to HIV-1 protease with molecular dynamics simulations and MM-GBSA calculations, SAR QSAR Environ. Res. 32 (2021), pp. 889–915. doi:10.1080/1062936X.2021.1979647.
   PubMed Web of Science ®Google Scholar
• Y. Gao, T. Zhu, and J. Chen, Exploring drug-resistant mechanisms of I84V mutation in HIV-1 protease toward different inhibitors by thermodynamics integration and solvated interaction energy method, Chem. Phys. Lett. 706 (2018), pp. 400–408. doi:10.1016/j.cplett.2018.06.040.
   Web of Science ®Google Scholar
• T. Hou, W.A. McLaughlin, and W. Wang, Evaluating the potency of HIV-1 protease drugs to combat resistance, Proteins 71 (2008), pp. 1163–1174. doi:10.1002/prot.21808.
   PubMed Web of Science ®Google Scholar
• T. Hou and R. Yu, Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors:  Mechanism for binding and drug resistance, J. Med. Chem. 50 (2007), pp. 1177–1188. doi:10.1021/jm0609162.
   PubMed Web of Science ®Google Scholar
• Y.X. Yu, W. Wang, H.B. Sun, L.L. Zhang, S.L. Wu, and W.T. Liu, Insights into effect of the Asp25/Asp25ʹ protonation states on binding of inhibitors amprenavir and MKP97 to HIV-1 protease using molecular dynamics simulations and MM-GBSA calculations, SAR QSAR Environ. Res. 32 (2021), pp. 615–641. doi:10.1080/1062936X.2021.1939149.
   PubMed Web of Science ®Google Scholar
• J. Chen, X. Wang, T. Zhu, Q. Zhang, and J.Z.H. Zhang, A comparative insight into amprenavir resistance of mutations V32I, G48V, I50V, I54V, and I84V in HIV-1 protease based on thermodynamic integration and MM-PBSA methods, J. Chem. Inf. Model. 55 (2015), pp. 1903–1913. doi:10.1021/acs.jcim.5b00173.
   PubMed Web of Science ®Google Scholar
• J. Chen, C. Peng, J. Wang, and W. Zhu, Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling, Proteins 86 (2018), pp. 1294–1305. doi:10.1002/prot.25610.
   PubMed Web of Science ®Google Scholar
• J. Chen, X. Liu, S. Zhang, J. Chen, H. Sun, L. Zhang, and Q. Zhang, Molecular mechanism with regard to the binding selectivity of inhibitors toward FABP5 and FABP7 explored by multiple short molecular dynamics simulations and free energy analyses, Phys. Chem. Chem. Phys. 22 (2020), pp. 2262–2275. doi:10.1039/C9CP05704H.
   PubMed Web of Science ®Google Scholar
• W. Wang and P.A. Kollman, Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance, Proc. Natl. Acad. Sci. USA 98 (2001), pp. 14937–14942.
   PubMed Web of Science ®Google Scholar
• L. Crisan and A. Bora, Small molecules of natural origin as potential anti-HIV agents: A computational approach, Life Sci. 11 (2021), pp. 722.
   Google Scholar
• S.S. Çınaroğlu and E. Timuçin, Comprehensive evaluation of the MM-GBSA method on bromodomain-inhibitor sets, Brief. Bioinform. 21 (2019), pp. 2112–2125. doi:10.1093/bib/bbz143.
   Web of Science ®Google Scholar
• M. Panda, P. Purohit, and B.R. Meher, Structure-based virtual screening, ADMET profiling, and molecular dynamics simulation studies on HIV-1 protease for identification of active phytocompounds as potential anti-HIV agents, Mol. Simulat. 48 (2022), pp. 1031–1049. doi:10.1080/08927022.2022.2060968.
   Web of Science ®Google Scholar
• R.K. Raju, N.A. Burton, and I.H. Hillier, Modelling the binding of HIV-reverse transcriptase and nevirapine: An assessment of quantum mechanical and force field approaches and predictions of the effect of mutations on binding, Phys. Chem. Chem. Phys. 12 (2010), pp. 7117–7125. doi:10.1039/c001384f.
   PubMed Web of Science ®Google Scholar
• J. Chen, W. Wang, H. Sun, L. Pang, and H. Bao, Binding mechanism of inhibitors to p38α MAP kinase deciphered by using multiple replica Gaussian accelerated molecular dynamics and calculations of binding free energies, Comput. Biol. Med. 134 (2021), pp. 104485. doi:10.1016/j.compbiomed.2021.104485.
   PubMed Web of Science ®Google Scholar
• J.Z.R. Martins, C. Chappey, M. Haddad, J.M. Whitcomb, E. Stawiski, C.J. Petropoulos, and S. Bonhoeffer, Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments, Epidemics-Neth 2 (2010), pp. 85–91. doi:10.1016/j.epidem.2010.03.003.
   PubMed Web of Science ®Google Scholar
• K.R. Karnati and Y. Wang, Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis, J. Mol. Graph. Model. 92 (2019), pp. 112–122. doi:10.1016/j.jmgm.2019.07.008.
   PubMed Web of Science ®Google Scholar
• S. Majumder and K. Giri, An insight into the binding mechanism of Viprinin and its morpholine and piperidine derivatives with HIV-1 Vpr: Molecular dynamics simulation, principal component analysis and binding free energy calculation study, J. Biomol. Struct. Dyn. (2021), pp. 1–13. doi:10.1080/07391102.2021.1954553.
   Web of Science ®Google Scholar
• L. Yang, G. Song, A. Carriquiry, and R.L. Jernigan, Close Correspondence between the motions from principal component analysis of multiple HIV-1 protease structures and elastic network modes, Structure 16 (2008), pp. 321–330. doi:10.1016/j.str.2007.12.011.
   PubMed Web of Science ®Google Scholar
• J. Chen, L. Wang, W. Wang, H. Sun, L. Pang, and H. Bao, Conformational transformation of switch domains in GDP/K-Ras induced by G13 mutants: An investigation through Gaussian accelerated molecular dynamics simulations and principal component analysis, Comput. Biol. Med. 135 (2021), pp. 104639. doi:10.1016/j.compbiomed.2021.104639.
   PubMed Web of Science ®Google Scholar
• F. Yan, X. Liu, S. Zhang, J. Su, Q. Zhang, and J. Chen, Molecular dynamics exploration of selectivity of dual inhibitors 5M7, 65X, and 65Z toward fatty acid binding proteins 4 and 5, Int. J. Mol. Sci. 19 (2018), pp. 2496. doi:10.3390/ijms19092496.
   PubMed Web of Science ®Google Scholar
• C. Tse, L. Wickstrom, M. Kvaratskhelia, E. Gallicchio, R. Levy, and N. Deng, Exploring the free-energy landscape and thermodynamics of protein-protein association, Biophys. J. 119 (2020), pp. 1226–1238. doi:10.1016/j.bpj.2020.08.005.
   PubMed Web of Science ®Google Scholar
• Q. Sun, R.M. Levy, K.A. Kirby, Z. Wang, S.G. Sarafianos, and N. Deng, Molecular dynamics free energy simulations reveal the mechanism for the antiviral resistance of the M66I HIV-1 capsid mutation, Viruses 13 (2021), pp. 920. doi:10.3390/v13050920.
   PubMed Web of Science ®Google Scholar
• Y. Li, L. Deng, L.-Q. Yang, P. Sang, and S.-Q. Liu, Effects of CD4 binding on conformational dynamics, molecular motions, and thermodynamics of HIV-1 gp120, Int. J. Mol. Sci. 20 (2019), pp. 260. doi:10.3390/ijms20020260.
   Web of Science ®Google Scholar
• J. Chen, S. Zhang, W. Wang, H. Sun, Q. Zhang, and X. Liu, Binding of inhibitors to BACE1 affected by ph-dependent protonation: An exploration from multiple replica Gaussian accelerated molecular dynamics and MM-GBSA calculations, ACS Chem. Neurosci. 12 (2021), pp. 2591–2607. doi:10.1021/acschemneuro.0c00813.
   PubMed Web of Science ®Google Scholar
• J. Chen, M. Yang, G. Hu, S. Shi, C. Yi, and Q. Zhang, Insights into the functional role of protonation states in the HIV-1 protease-BEA369 complex: Molecular dynamics simulations and free energy calculations, J. Mol. Model. 15 (2009), pp. 1245–1252. doi:10.1007/s00894-009-0452-y.
   PubMed Web of Science ®Google Scholar
• W.E. Harte and D.L. Beveridge, Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation, J. Am. Chem. Soc. 115 (1993), pp. 3883–3886. doi:10.1021/ja00063a005.
   Web of Science ®Google Scholar
• J. Chen, Z. Liang, W. Wang, C. Yi, S. Zhang, and Q. Zhang, Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations, Sci. Rep-UK 4 (2014), pp. 6872. doi:10.1038/srep06872.
   PubMed Web of Science ®Google Scholar
• D.C. Bas, D.M. Rogers, and J.H. Jensen, Very fast prediction and rationalization of pKa values for protein–ligand complexes, Proteins 73 (2008), pp. 765–783. doi:10.1002/prot.22102.
   PubMed Web of Science ®Google Scholar
• H. Li, A.D. Robertson, and J.H. Jensen, Very fast empirical prediction and rationalization of protein pKa values, Proteins 61 (2005), pp. 704–721. doi:10.1002/prot.20660.
   PubMed Web of Science ®Google Scholar
• J.A. Maier, C. Martinez, K. Kasavajhala, L. Wickstrom, K.E. Hauser, and C. Simmerling, ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB, J. Chem. Theory Comput. 11 (2015), pp. 3696–3713. doi:10.1021/acs.jctc.5b00255.
   PubMed Web of Science ®Google Scholar
• A. Jakalian, B.L. Bush, D.B. Jack, and C.I. Bayly, Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I, Method, J. Comput. Chem. 21 (2000), pp. 132–146. doi:10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P.
   Web of Science ®Google Scholar
• A. Jakalian, D.B. Jack, and C.I. Bayly, Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation, J. Comput. Chem. 23 (2002), pp. 1623–1641. doi:10.1002/jcc.10128.
   PubMed Web of Science ®Google Scholar
• J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case, Development and testing of a general amber force field, J. Comput. Chem. 25 (2004), pp. 1157–1174. doi:10.1002/jcc.20035.
   PubMed Web of Science ®Google Scholar
• D. Vassetti, M. Pagliai, and P. Procacci, Assessment of GAFF2 and OPLS-AA general force fields in combination with the water models TIP3P, SPCE, and OPC3 for the solvation free energy of druglike organic molecules, J. Chem. Theory Comput. 15 (2019), pp. 1983–1995. doi:10.1021/acs.jctc.8b01039.
   PubMed Web of Science ®Google Scholar
• J.A. Izaguirre, D.P. Catarello, J.M. Wozniak, and R.D. Skeel, Langevin stabilization of molecular dynamics, J. Chem. Phys. 114 (2001), pp. 2090–2098. doi:10.1063/1.1332996.
   Web of Science ®Google Scholar
• J.-P. Ryckaert, G. Ciccotti, and H.J.C. Berendsen, Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes, J. Comput. Phys. 23 (1977), pp. 327–341. doi:10.1016/0021-9991(77)90098-5.
   Web of Science ®Google Scholar
• T. Darden, D. York, and L. Pedersen, Particle mesh ewald: An N ⋅log(N) method for ewald sums in large systems, J. Chem. Phys. 98 (1993), pp. 10089–10092. doi:10.1063/1.464397.
   Web of Science ®Google Scholar
• U. Essmann, L. Perera, M.L. Berkowitz, T. Darden, H. Lee, and L.G. Pedersen, A smooth particle mesh ewald method, J. Chem. Phys. 103 (1995), pp. 8577–8593. doi:10.1063/1.470117.
   Web of Science ®Google Scholar
• J. Chen, W. Wang, H. Sun, L. Pang, and B. Yin, Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics, J. Comput. Aid. Mol. Des. 34 (2020), pp. 1289–1305. doi:10.1007/s10822-020-00355-5.
   PubMed Web of Science ®Google Scholar
• D.R. Roe and T.E. Cheatham, PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data, J. Chem. Theory Comput. 9 (2013), pp. 3084–3095. doi:10.1021/ct400341p.
   PubMed Web of Science ®Google Scholar
• W. Humphrey, A. Dalke, and K. Schulten, VMD: Visual molecular dynamics, J. Mol. Graph. 14 (1996), pp. 33–38. doi:10.1016/0263-7855(96)00018-5.
   PubMed Web of Science ®Google Scholar
• M.R. Shirts, J.W. Pitera, W.C. Swope, and V.S. Pande, Extremely precise free energy calculations of amino acid side chain analogs: Comparison of common molecular mechanics force fields for proteins, J. Chem. Phys. 119 (2003), pp. 5740–5761. doi:10.1063/1.1587119.
   Web of Science ®Google Scholar
• W. Wang and P.A. Kollman, Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model11Edited by B, Honig, J. Mol. Biol. 303 (2000), pp. 567–582. doi:10.1006/jmbi.2000.4057.
   PubMed Web of Science ®Google Scholar
• W. Wang and P.A. Kollman, Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance, Proc. Natl. Acad. Sci. 98 (2001), pp. 14937–14942. doi:10.1073/pnas.251265598.
   PubMed Web of Science ®Google Scholar
• M. Ylilauri and O.T. Pentikäinen, MMGBSA as a tool to understand the binding affinities of filamin–peptide interactions, J. Chem. Inf. Model. 53 (2013), pp. 2626–2633. doi:10.1021/ci4002475.
   PubMed Web of Science ®Google Scholar
• E.A. Rifai, M. Van Dijk, N.P.E. Vermeulen, A. Yanuar, and D.P. Geerke, A comparative linear interaction energy and MM/PBSA study on SIRT1–ligand binding free energy calculation, J. Chem. Inf. Model. 59 (2019), pp. 4018–4033. doi:10.1021/acs.jcim.9b00609.
   PubMed Web of Science ®Google Scholar
• J. Su, X. Liu, S. Zhang, F. Yan, Q. Zhang, and J. Chen, Insight into selective mechanism of class of I-BRD9 inhibitors toward BRD9 based on molecular dynamics simulations, Chem. Biol. Drug Des. 93 (2019), pp. 163–176. doi:10.1111/cbdd.13398.
   PubMed Web of Science ®Google Scholar
• K.S. Schaller, J. Kari, G.A. Molina, K.D. Tidemand, K. Borch, G.H.J. Peters, and P. Westh, Computing cellulase kinetics with a two-domain linear interaction energy approach, ACS Omega 6 (2021), pp. 1547–1555. doi:10.1021/acsomega.0c05361.
   PubMed Web of Science ®Google Scholar
• H. Sun, Y. Li, M. Shen, S. Tian, L. Xu, P. Pan, Y. Guan, and T. Hou, Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring, Phys. Chem. Chem. Phys. 16 (2014), pp. 22035–22045. doi:10.1039/C4CP03179B.
   PubMed Web of Science ®Google Scholar
• H. Sun, Y. Li, S. Tian, L. Xu, and T. Hou, Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set, Phys. Chem. Chem. Phys. 16 (2014), pp. 16719–16729. doi:10.1039/C4CP01388C.
   PubMed Web of Science ®Google Scholar
• H. Gohlke, C. Kiel, and D.A. Case, Insights into protein–protein binding by binding free energy calculation and free energy decomposition for the Ras–Raf and Ras–RalGDS complexes, J. Mol. Biol. 330 (2003), pp. 891–913. doi:10.1016/S0022-2836(03)00610-7.
   PubMed Web of Science ®Google Scholar
• J. Chen, Drug resistance mechanisms of three mutations V32I, I47V and V82I in HIV-1 protease toward inhibitors probed by molecular dynamics simulations and binding free energy predictions, RSC Adv. 6 (2016), pp. 58573–58585. doi:10.1039/C6RA09201B.
   Web of Science ®Google Scholar
• B.R. Meher and Y. Wang, Interaction of I50V mutant and i50L/A71V double mutant HIV-protease with inhibitor TMC114 (Darunavir): Molecular dynamics simulation and binding free energy studies, J. Phys. Chem. B 116 (2012), pp. 1884–1900. doi:10.1021/jp2074804.
   PubMed Web of Science ®Google Scholar
• R. Wang and Q. Zheng, Multiple molecular dynamics simulations of the inhibitor GRL-02031 complex with wild type and mutant HIV-1 protease reveal the binding and drug-resistance mechanism, Langmuir 36 (2020), pp. 13817–13832. doi:10.1021/acs.langmuir.0c02151.
   PubMed Web of Science ®Google Scholar